Tourmaline Bio (TRML) News Today $16.30 -1.55 (-8.68%) Closing price 04:00 PM EasternExtended Trading$17.01 +0.71 (+4.35%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 2 at 7:30 AM | globenewswire.comNantahala Capital Management LLC Lowers Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Nantahala Capital Management LLC trimmed its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 23.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 536,944 shares of the companApril 30 at 8:15 AM | marketbeat.comAdage Capital Partners GP L.L.C. Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Adage Capital Partners GP L.L.C. bought a new stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 600,000 shares of the company's stock, valuedApril 30 at 5:30 AM | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Position Trimmed by Marshall Wace LLPMarshall Wace LLP cut its stake in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 16.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 116,091 shares of the company's stock after selling 22,103 shares during the quApril 29 at 4:07 AM | marketbeat.comChardan Capital Forecasts Tourmaline Bio FY2025 EarningsApril 29 at 2:11 AM | americanbankingnews.comChardan Capital Weighs in on Tourmaline Bio FY2025 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Tourmaline Bio in a research report issued on Wednesday, April 23rd. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings ofApril 29 at 2:05 AM | marketbeat.comBlue Owl Capital Holdings LP Sells 451,080 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)Blue Owl Capital Holdings LP trimmed its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 29.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,079,321 shares of the company'sApril 26, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Earns Buy Rating from Analysts at Chardan CapitalApril 26, 2025 | americanbankingnews.comTourmaline Bio (NASDAQ:TRML) Coverage Initiated at Chardan CapitalChardan Capital assumed coverage on shares of Tourmaline Bio in a research report on Wednesday. They issued a "buy" rating and a $70.00 price target for the company.April 25, 2025 | marketbeat.comKrystal Biotech (NASDAQ:KRYS) and Tourmaline Bio (NASDAQ:TRML) Head-To-Head ComparisonApril 24, 2025 | americanbankingnews.comTourmaline Bio initiated with a Buy at ChardanApril 23, 2025 | markets.businessinsider.comTourmaline Bio (TRML) Gets a Buy from Chardan CapitalApril 23, 2025 | markets.businessinsider.comChardan Capital Initiates Coverage of Tourmaline Bio (TRML) with Buy RecommendationApril 23, 2025 | msn.comNan Fung Group Holdings Ltd Acquires 40,290 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)Nan Fung Group Holdings Ltd grew its stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 27.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 187,090 shares of the company's stock after purchasing an additional 40,290 shApril 21, 2025 | marketbeat.comHere's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn SituationApril 19, 2025 | finance.yahoo.comVanguard Group Inc. Boosts Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)Vanguard Group Inc. grew its position in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,106,125 shares of the company's stock after purchasinApril 17, 2025 | marketbeat.comAmerican Century Companies Inc. Purchases New Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)American Century Companies Inc. acquired a new position in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 23,357 shares of the company's stock, valuedApril 14, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Rating of "Buy" by BrokeragesShares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have been given a consensus rating of "Buy" by the six research firms that are currently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target prApril 12, 2025 | marketbeat.comTourmaline Bio price target lowered to $63 from $74 at TruistApril 11, 2025 | markets.businessinsider.comPolymer Capital Management HK LTD Acquires Shares of 79,400 Tourmaline Bio, Inc. (NASDAQ:TRML)Polymer Capital Management HK LTD purchased a new stake in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 79,400 shares of the company's stApril 8, 2025 | marketbeat.comPictet Asset Management Holding SA Boosts Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)Pictet Asset Management Holding SA increased its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 69.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 419,883 shares of the companyApril 4, 2025 | marketbeat.comTourmaline Bio: We Should Wait For Upcoming Phase 2b Trial DataApril 3, 2025 | seekingalpha.comTruist biotech analyst holds an analyst/industry conference callApril 2, 2025 | markets.businessinsider.comSwiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML)Swiss National Bank bought a new position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 20,100 shares of the company's stock, valued at approximately $4March 31, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by AnalystsShares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have been assigned a consensus rating of "Buy" from the eight research firms that are presently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year priMarch 16, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Given New $43.00 Price Target at WedbushWedbush upped their target price on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Friday.March 15, 2025 | marketbeat.comTOURMALINE BIO Earnings Results: $TRML Reports Quarterly EarningsMarch 15, 2025 | nasdaq.comTourmaline Bio (TRML) Gets a Buy from WedbushMarch 15, 2025 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright increased their price target on shares of Tourmaline Bio from $49.00 to $50.00 and gave the company a "buy" rating in a research report on Friday.March 15, 2025 | marketbeat.comTourmaline Bio price target raised to $43 from $42 at WedbushMarch 14, 2025 | markets.businessinsider.comTourmaline Bio (NASDAQ:TRML) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPSTourmaline Bio (NASDAQ:TRML - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.05.March 14, 2025 | marketbeat.comTourmaline Bio, Inc.: Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 14, 2025 | finanznachrichten.deTourmaline Bio reports Q4 EPS (86c), consensus (87c)March 14, 2025 | markets.businessinsider.comTourmaline Bio shares fall as Q4 loss widensMarch 14, 2025 | investing.comTourmaline Bio sees cash runway into 2H27March 14, 2025 | markets.businessinsider.comTourmaline Bio’s 2024 Financial Results and Strategic AdvancesMarch 14, 2025 | tipranks.comTourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial OutlookMarch 13, 2025 | quiverquant.comTourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 13, 2025 | globenewswire.comTourmaline Bio (TRML) Projected to Post Earnings on TuesdayTourmaline Bio (NASDAQ:TRML) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Tourmaline Bio (TRML)March 10, 2025 | markets.businessinsider.comWedbush Forecasts Tourmaline Bio FY2024 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued to investors on Thursday, March 6th. Wedbush analyst L. Chico anticipates that the company will earn ($2.78) per share for the year. WedbMarch 10, 2025 | marketbeat.comWedbush bullish on Tourmaline Bio, initiates with an OutperformMarch 7, 2025 | markets.businessinsider.comWedbush Initiates Coverage of Tourmaline Bio (TRML) with Outperform RecommendationMarch 7, 2025 | msn.comTourmaline Bio (NASDAQ:TRML) Earns Outperform Rating from Analysts at WedbushWedbush assumed coverage on shares of Tourmaline Bio in a research report on Thursday. They issued an "outperform" rating and a $42.00 price objective for the company.March 7, 2025 | marketbeat.comTourmaline Bio initiated with an Outperform at WedbushMarch 6, 2025 | markets.businessinsider.comTourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025March 3, 2025 | globenewswire.comTruist Financial Sticks to Their Buy Rating for Tourmaline Bio (TRML)February 27, 2025 | markets.businessinsider.comLifesci Capital Estimates Tourmaline Bio FY2024 EarningsTourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities research analysts at Lifesci Capital issued their FY2024 earnings estimates for shares of Tourmaline Bio in a report issued on Monday, February 24th. Lifesci Capital analyst R. Katkhuda anticipates that the company will earn ($2.89) perFebruary 26, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of Tourmaline Bio (TRML) with Outperform RecommendationFebruary 25, 2025 | msn.comTourmaline Bio initiated with an Outperform at LifeSci CapitalFebruary 24, 2025 | markets.businessinsider.com Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address TRML Media Mentions By Week TRML Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRML News Sentiment▼1.260.83▲Average Medical News Sentiment TRML News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRML Articles This Week▼123▲TRML Articles Average Week Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IDEAYA Biosciences News Arcutis Biotherapeutics News Travere Therapeutics News Agios Pharmaceuticals News Harmony Biosciences News Edgewise Therapeutics News Disc Medicine News Indivior News Kiniksa Pharmaceuticals News ANI Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRML) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRML Stock Free TRML Stock Alerts